Artículo

Melatonin is an effective protector of gingival cells damaged by the cytotoxic effect of glutamate and DL-buthionine sulfoximine

Solá, Verónica Mariana Icon; Aguilar, Juan Javier ; Vazquez Mosquera, Ana Paula ; Carpentieri, Agata Rita Icon

Otros responsables

Fecha

01/2021

Editorial

Wiley Blackwell Publishing, Inc

Revista

Journal Of Periodontal Research

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0022-3484

eISSN

1600-0765

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Cellular damage related to oxidative stress (OS) is implicated in periodontal diseases (PD). Melatonin (MEL) has multiple functions, and it has been described as a potential treatment for PD. We aim at evaluating the protective effects of MEL on an in vitro model of cellular damage triggered by glutamate (GLUT) and DL-buthionine sulfoximine (BSO), on gingival cells (GCs) in culture. Material and Methods: A primary culture of GCs from Wistar rats was developed in order to test the protective property of MEL; BSO and GLUT were administered alone as well as in combination with MEL. The viability and apoptosis were measured with MTT assay and TUNEL, respectively, and the concentration of superoxide anion (O2-) was measured with the NBT method. Results: The combination of BSO and GLUT treatment resulted in a decreased viability of GCs. This was evidenced by the increase in both the production of superoxide anion and apoptosis. After MEL administration, the oxidant and pro-apoptotic effects of BSO and GLUT were totally counteracted. Conclusions: These findings demonstrated that MEL has an effective protective role on GCs subjected to cellular damage in a model of OS and cytotoxicity triggered by BSO and GLUT. Consequently, MEL could be used as a therapeutic agent in PD which begin with a significative loss of GCs.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa